"Patients are allowed to enrolle if they have a stable or falling prostate-specific antigen (PSA) level below 0.2 ng/mL and a castrate testosterone level under 50 ng/dL at baseline after having a PSA level of at least 5 ng/mL and a testosterone level of at least 150 ng/dL prior to the start of ADT. "
"This ongoing trial seeks to redefine management strategies for mHSPC by integrating periods of treatment interruption based on robust initial responses with the goal of improving QOL without affecting treatment outcomes."
Non inferiority would already be a great outcome, let's hope!
Appointment with Provenge doctor
NCT04662580 - All about ARX517 as Monotherapy
primary tumor
Help Understanding My Dad's Biopsy Scores
A technical question on Radiation
